AstraZeneca PLC (AZN.LN) and Merck & Co. Inc. (MRK) on Friday said the U.S. Food and Drug Administration has approved a new tablet form of the ovarian cancer treatment Lynparza.
The two drug companies are collaborating on developing and marketing Lynparza, which was initially developed by AstraZeneca.
Continue Reading Below
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
August 18, 2017 02:34 ET (06:34 GMT)